1 Min Read
April 26 (Reuters) -
* Midazolam nasal spray (usl261) phase 3 trial meets primary efficacy endpoint in patients with seizure clusters Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.